Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia.
acute myeloid leukemia (AML)
autologous stem cell transplantation (ASCT)
gemtuzumab ozogamicin (GO)
peripheral blood stem cells (PBSC)
stem cell mobilization
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
30
05
2024
revised:
17
07
2024
accepted:
18
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
27
7
2024
Statut:
epublish
Résumé
Gemtuzumab ozogamicin (GO), a CD33-targeting antibody drug conjugate, previously showed longer relapse-free survival when combined with induction chemotherapy in patients with favorable-risk acute myeloid leukemia (AML). In this patient population, characterized by lower relapse risk as compared to other ELN risk groups, autologous stem cell transplantation (ASCT) can be used as consolidation strategy. However, there are limited data on the impact of GO on the peripheral blood stem cell (PBSC) mobilization potential. We therefore retrospectively analyzed data from 54 AML patients with favorable-risk AML treated with (
Identifiants
pubmed: 39062189
pii: biomedicines12071616
doi: 10.3390/biomedicines12071616
pii:
doi:
Types de publication
Journal Article
Langues
eng